Neutralises oxidative stress protecting cells from free radical damage (a cause of dullness, wrinkles, and inflammation)
The SURMOUNT-1 trial showed that tirzepatide, a dual GIP/GLP-1 receptor agonist, produced even greater weight loss (up to 20.9% at the highest dose) with proportional reductions in waist circumference
Our rigorous methodology included exclusively focusing on RCTs, ensuring high-quality evidence while minimizing potential bias
Your provider will need to write a new prescription for the compounded formulation and may need to document a clinical justification
Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) due to thyroid C-cell tumor findings in rodent studies
For some, the once-weekly injection may be more convenient than daily pills